The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma

Resistance to the proteasome inhibitor bortezomib (BTZ) represents a major obstacle in the treatment of multiple myeloma (MM). The contribution of lipid metabolism in the resistance of MM cells to BTZ is mostly unknown. Here we report that levels of fatty acid elongase 6 (ELOVL6) were lower in MM ce...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Lipchick, Brittany C., Utley, Adam, Han, Zhannan, Moparthy, Sudha, Yun, Dong Hyun, Bianchi-Smiraglia, Anna, Wolff, David W., Fink, Emily, Liu, Liang, Furdui, Cristina M., Lee, Jingyun, Lee, Kelvin P., Nikiforov, Mikhail A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2021
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045499/
https://ncbi.nlm.nih.gov/pubmed/33821992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002578
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi